Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31629565 | 0.85 | POLB (0.49) | POLBADORA1SLC29A1 | |
| SCHEMBL29514600 | 0.85 | KDM4E (0.56) | POLBADORA1SLC29A1 | |
| SCHEMBL15143709 | 0.85 | POLB (0.61) | POLBADORA1SLC29A1 | |
| SCHEMBL19519648 | 0.85 | POLB (0.61) | POLBADORA1SLC29A1 | |
| SCHEMBL11683614 | 0.85 | POLB (0.61) | POLBADORA1SLC29A1 | |
| SCHEMBL12362206 | 0.85 | POLB (0.61) | POLBADORA1SLC29A1 | |
| SCHEMBL4727394 | 0.84 | ADORA1 (0.46) | POLBADORA1SLC29A1 | |
| SCHEMBL4727404 | 0.84 | ADORA1 (0.46) | POLBADORA1SLC29A1 | |
| SCHEMBL11049246 | 0.84 | POLB (0.51) | POLBADORA1SLC29A1 | |
| SCHEMBL20534948 | 0.84 | POLB (0.51) | POLBADORA1SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227798-B2 | Methods and compositions for incorporating nucleotides | IsoPlexis Corporation (US) | 2025-02-18 | — | — | US | disclosed |
| US-20250052717-A1 | METHODS AND DEVICES FOR SEQUENCING NUCLEIC ACIDS IN SMALLER BATCHES | QIAGEN SCIENCES, LLC | 2025-02-13 | — | — | US | disclosed |
| US-11940413-B2 | Methods and devices for sequencing nucleic acids in smaller batches | IsoPlexis Corporation (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240076731-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN SCIENCES, LLC | 2024-03-07 | — | — | US | disclosed |
| US-20240060128-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN WALTHAM, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230407384-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | QIAGEN WALTHAM, INC. | 2023-12-21 | — | — | US | disclosed |
| EP-4162035-A2 | MODIFIED TEMPLATE-INDEPENDENT ENZYMES FOR POLYDEOXYNUCLEOTIDE SYNTHESIS | Molecular Assemblies Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11390858-B2 | Modified template-independent enzymes for polydeoxynucleotide synthesis | Molecular Assemblies, Inc. (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227798-B2 | Methods and compositions for incorporating nucleotides | NT5C2, NOP2, NT5C3B | P2RY12 387/4885POLB 44/4885ADORA1 488/4885 |
| US-20240076731-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | P2RY12 387/4885POLB 44/4885ADORA1 488/4885 |
| US-20230407384-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | P2RY12 387/4885POLB 44/4885ADORA1 488/4885 |
| US-20240060128-A1 | METHODS AND COMPOSITIONS FOR INCORPORATING NUCLEOTIDES | NT5C2, NOP2, NT5C3B | P2RY12 387/4885POLB 44/4885ADORA1 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.